Alexion Pharmaceuticals reports that the European Commission has approved the new 100 mg/mL intravenous formulation of ULTOMIRIS® (ravulizumab) for the treatment of two ultra-rare diseases: paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
“ULTOMIRIS has already provided patients with greater flexibility and this new formulation is another step forward in reducing the overall treatment burden,” said Professor Alexander Röth, Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.